Technology evaluation: alicaforsen (Isis).

Article Details

Citation
Copy to clipboard

Gewirtz AT, Sitaraman SV

Technology evaluation: alicaforsen (Isis).

Curr Opin Mol Ther. 2005 Jun;7(3):273-81.

PubMed ID
15977426 [ View in PubMed
]
Abstract

Isis is developing alicaforsen, an RNase H-dependent antisense inhibitor of intercellular adhesion molecule-1, for the potential treatment of ulcerative colitis. The therapy is currently undergoing phase II clinical trials.

DrugBank Data that Cites this Article

Drugs